Zosuquidar是Pgp介导的多药抗性调节剂,Ki为60 nM。
Zosuquidar (LY335979) 3HCl is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM in a cell-free assay. Phase 3.
0.05 μM -5 μM
≤30 mg/kg 腹腔注射或静脉注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Dantzig AH, et al. Cancer Res. 1996, 56(18), 4171-4179.
[2] Dantzig et al (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J.Pharmacol.Exp.Ther. 290 854.
分子式 C32H34Cl3F2N3O2 |
分子量 636.99 |
CAS号 167465-36-3 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 100 mg/mL |
Water 20 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00233909 | Leukemia, Myeloid | Drug: Zosuquidar|Drug: gemtuzumab ozogamicin | Kanisa Pharmaceuticals | Phase 1|Phase 2 | 2005-10-01 | 2008-03-28 |
NCT00046930 | Leukemia|Myelodysplastic Syndromes | Biological: filgrastim|Biological: sargramostim|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: zosuquidar trihydrochloride|Drug: Placebo | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|Kanisa Pharmaceuticals | Phase 3 | 2002-07-01 | 2015-06-01 |
NCT00129168 | Leukemia, Myeloid | Drug: Zosuquidar|Drug: Daunorubicin|Drug: Cytarabine | Kanisa Pharmaceuticals | Phase 1|Phase 2 | 2005-08-01 | 2008-03-28 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们